- Home
- AVTE
as 07-26-2024 4:00pm EST
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 50.4M | IPO Year: | 2021 |
| Target Price: | $11.75 | AVG Volume (30 days): | 715.8K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.25 - $32.41 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Aerovate Therapeutics Inc. (AVTE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | AVTE | Director10% Owner | Jun 17 '24 | Buy | $1.67 | 928,110 | $1,549,943.70 | 7,893,678 | SEC Form 4 |
| Verwijs Marinus | AVTE | CHIEF TECHNICAL OFFICER | Jun 14 '24 | Sell | $25.00 | 10,600 | $265,000.00 | 0 | SEC Form 4 |
| Eldridge George A | AVTE | SEE REMARKS | Jun 14 '24 | Sell | $25.03 | 15,000 | $375,450.00 | 5,022 | SEC Form 4 |
| Gillies Hunter | AVTE | CHIEF MEDICAL OFFICER | Jun 13 '24 | Sell | $24.50 | 6,000 | $147,000.00 | 5,602 | SEC Form 4 |
| Gillies Hunter | AVTE | CHIEF MEDICAL OFFICER | May 17 '24 | Sell | $21.07 | 3,914 | $82,451.54 | 5,688 | SEC Form 4 |
| Gillies Hunter | AVTE | CHIEF MEDICAL OFFICER | May 17 '24 | Sell | $21.86 | 86 | $1,879.96 | 5,602 | SEC Form 4 |
| NOYES TIMOTHY P | AVTE | CHIEF EXECUTIVE OFFICER | May 16 '24 | Sell | $21.52 | 8,707 | $187,410.34 | 1,293 | SEC Form 4 |
| NOYES TIMOTHY P | AVTE | CHIEF EXECUTIVE OFFICER | May 16 '24 | Sell | $21.92 | 1,293 | $28,345.15 | 0 | SEC Form 4 |
| Verwijs Marinus | AVTE | CHIEF TECHNICAL OFFICER | May 2 '24 | Sell | $21.02 | 1,981 | $41,630.72 | 0 | SEC Form 4 |
| NOYES TIMOTHY P | AVTE | CHIEF EXECUTIVE OFFICER | May 1 '24 | Sell | $20.34 | 9,035 | $183,792.68 | 965 | SEC Form 4 |
| NOYES TIMOTHY P | AVTE | CHIEF EXECUTIVE OFFICER | May 1 '24 | Sell | $20.87 | 965 | $20,135.01 | 0 | SEC Form 4 |
| NOYES TIMOTHY P | AVTE | CHIEF EXECUTIVE OFFICER | May 1 '24 | Sell | $19.91 | 1,357 | $27,017.87 | 0 | SEC Form 4 |
| Dake Benjamin T | AVTE | SEE REMARKS | Apr 17 '24 | Sell | $22.32 | 6,447 | $143,865.45 | 1,697 | SEC Form 4 |
| Dake Benjamin T | AVTE | SEE REMARKS | Apr 17 '24 | Sell | $23.17 | 338 | $7,831.43 | 1,359 | SEC Form 4 |
| Dake Benjamin T | AVTE | SEE REMARKS | Apr 17 '24 | Sell | $23.97 | 68 | $1,629.96 | 1,291 | SEC Form 4 |
| Gillies Hunter | AVTE | CHIEF MEDICAL OFFICER | Apr 17 '24 | Sell | $22.30 | 3,689 | $82,266.91 | 3,562 | SEC Form 4 |
| Gillies Hunter | AVTE | CHIEF MEDICAL OFFICER | Apr 17 '24 | Sell | $23.33 | 311 | $7,254.91 | 3,251 | SEC Form 4 |
| NOYES TIMOTHY P | AVTE | CHIEF EXECUTIVE OFFICER | Apr 16 '24 | Sell | $24.40 | 4,491 | $109,560.64 | 5,509 | SEC Form 4 |
| NOYES TIMOTHY P | AVTE | CHIEF EXECUTIVE OFFICER | Apr 16 '24 | Sell | $24.94 | 5,509 | $137,409.89 | 0 | SEC Form 4 |
| Eldridge George A | AVTE | SEE REMARKS | Apr 10 '24 | Sell | $27.56 | 771 | $21,252.31 | 1,960 | SEC Form 4 |
| Eldridge George A | AVTE | SEE REMARKS | Apr 10 '24 | Sell | $26.77 | 6,729 | $180,139.37 | 2,731 | SEC Form 4 |
| GRAYZEL DAVID S. | AVTE | Director | Apr 9 '24 | Sell | $28.15 | 11,882 | $334,478.30 | 14,502 | SEC Form 4 |
| NOYES TIMOTHY P | AVTE | CHIEF EXECUTIVE OFFICER | Apr 1 '24 | Sell | $28.96 | 4,502 | $130,399.08 | 5,498 | SEC Form 4 |
| NOYES TIMOTHY P | AVTE | CHIEF EXECUTIVE OFFICER | Apr 1 '24 | Sell | $29.90 | 1,647 | $49,237.89 | 3,851 | SEC Form 4 |
| NOYES TIMOTHY P | AVTE | CHIEF EXECUTIVE OFFICER | Apr 1 '24 | Sell | $31.02 | 2,851 | $88,446.00 | 1,000 | SEC Form 4 |
Latest Aerovate Therapeutics Inc. News
AVTE Breaking Stock News: Dive into AVTE Ticker-Specific Updates for Smart Investing
MT Newswires
18 days ago
Aerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown
BioPharma Dive
18 days ago
Ligand to buy Apeiron; Roche reports another TIGIT setback
GlobeNewswire
18 days ago
Aerovate Therapeutics to Explore Strategic Alternatives
Clinical Trials Arena
24 days ago
Aerovate slashes workforce after failed Phase IIb trial
Zacks
a month ago
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
MT Newswires
a month ago
--Guggenheim Downgrades Aerovate Therapeutics to Neutral From Buy
MT Newswires
a month ago
--TD Cowen Downgrades Aerovate Therapeutics to Hold From Buy
Barrons.com
a month ago
Aerovate Therapeutics Stock Dropped Over 90%. Here’s Why.
Compare AVTE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVTE Aerovate Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.